Evidence map›Paper›PMID 33529945›Full record

SynthesisBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021

Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review.

Saniya Mahendiratta, Seema Bansal, Phulen Sarma, Harish Kumar, Gajendra Choudhary, Subodh Kumar, Ajay Prakash, Rakesh Sehgal, Bikash Medhi

Open access · goldAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 3 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Saniya MahendirattaDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: saniya.mahendiratta88@gmail.com.
Seema BansalPost Graduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: 2006.seema@gmail.com.
Phulen SarmaDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: phulen10@gmail.com.
Harish KumarDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: hkumar98@gmail.com.
Gajendra ChoudharyDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: gajendra809@gmail.com.
Subodh KumarPGIMER, Chandigarh, India. Electronic address: subodhbiotech@gmail.com.
Ajay PrakashDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: ajayprakashpgi@gmail.com.
Rakesh SehgalDept. of Parasitology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: sehgalpgi@gmail.com.
Bikash MedhiDepartment of Pharmacology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Electronic address: drbikashus@yahoo.com.
Post Graduate Institute of Medical Education and Research · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSARS-CoV-2, which majorly affects the lungs and respiratory tract is thought due to dysregulation of the immune system which causes an immense imbalance of the cytokines. However, till now no standard treatment has been developed in treating the disease. On the other hand, it becomes important to prevent the acute respiratory tract infection due to COVID-19 which is the most dangerous phase leading to increased mortality. Hence this systematic review has been framed by pooling the available data of the use of stem cells in SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS.

methods6 literature databases (PubMed, EMBASE, Scopus, Google Scholar, Clinicaltrials.gov, and Clinical trial registry of India) were searched for relevant studies till 10th August 2020 using keywords stem cells, mesenchymal stem cells, cell therapy, SARS CoV-2, SARS Coronavirus, Coronavirus 2, COVID-19, nCoV-19, Novel Coronavirus, MERS CoV, ARDS, acute respiratory distress syndrome.

resultsThe observations of this systematic review suggest capability of MSCs in reducing the systemic inflammation and protecting against SARS-CoV-2 as evidenced by the available clinical data.

conclusionMSCs can overcome the clinical challenges currently faced by SARS-CoV-2 infected patients, specifically who are seriously ill and not responding to conventional therapies. Though the available clinical data is motivating, still predicting the therapeutic potential of MSCs will be too early in COVID-19. Hence, further studies in a larger cohort of patients becomes a prerequisite to validate their potential efficacy.

Indexed as

COVID-19SARS-CoV-2Coronavirus InfectionsHumansImmunomodulationMesenchymal Stem Cell TransplantationARDSCoronavirusImmunomodulatorySARS-CoV-2Stem cell therapy

Identifiers

PMID33529945
PMCPMC7843034
OpenAlexW3121688104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.